The share price is now at 27.98% for the past six months.
Advertisement
Cepheid (NASDAQ:CPHD) is expected to release the earnings of its current quarter on 10/18/16.
On the company’s financial health, Danaher Corporation reported $1.25 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 25, 2016. The performance this quarter is at 5.44% while the weekly performance is at -2.86%. Based on its public disclosures, Cepheid generated annual revenues of $539 million in 2015, with double-digit year-on-year organic revenue growth and greater than 75% of these revenues considered recurring.
While looking at the Stock’s Performance, Danaher Corporation now shows a Weekly Performance of -2.86%, where Monthly Performance is -2.45%, Quarterly performance is 5.44%, 6 Months performance is 18.28% and yearly performance percentage is 23.3%.
In an overview of the current analyst recommendations, Buy count is 10 and Overweight is 1 while the number of analysts recommending Sell and Underweight are 0 and 0, respectively. The share price of the stock plunged -49.14% for the year. Canaccord Genuity reaffirmed a “hold” rating and issued a $32.00 target price on shares of Cepheid in a research note on Wednesday, June 29th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus analyst price target of $24.01for twelve month. Its stock inched up 6 cents to $107.50. Envestnet Asset Management Inc. boosted its stake in Cepheid by 17.4% in the first quarter. Volume of trade was was down over the average, with 1,591,760 shares of DHR changing hands under the typical 3,420,520 shares. Signaturefd LLC boosted its position in shares of Danaher Corp.by 7.7% in the second quarter. Following the completion of the transaction, the vice president now owns 10,721 shares in the company, valued at $393,567.91.
Mr. Bishop explained that working with Danaher’s $5 billion Diagnostics platform will allow the company to accelerate its reach to customers and patients in a faster way as compared to how it did single-handedly.
The deal is subject to customary closing conditions, including Cepheid-shareholder and regulatory approval, and is expected to close by the end of the year. The stock’s weekly volatility was 1.50% and the RSI amounts to 35.33.
Danaher expects to finance the transaction with available cash and proceeds from the issuance of debt.
Advertisement
In addition to Barclays Capital reporting it’s stock price target, a total of 20 firms have reported on the company. The number of shares now owned by investors are 1.96 bln.
